With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Macular Degeneration (AMD) and Other Retinal Diseases market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Macular Degeneration (AMD) and Other Retinal Diseases market in terms of revenue.
Players, stakeholders, and other participants in the global Macular Degeneration (AMD) and Other Retinal Diseases market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Macular Degeneration (AMD) and Other Retinal Diseases market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Macular Degeneration (AMD) and Other Retinal Diseases market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Macular Degeneration (AMD) and Other Retinal Diseases market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Macular Degeneration (AMD) and Other Retinal Diseases market.
The following players are covered in this report:
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
Merck
Allergan
Santen Pharmaceutical
GlaxoSmithKline Pharmaceuticals
Pfizer
Acucela
Valent Pharmaceuticals
IVERIC
Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Type
Macular Degeneration
Diabetic Macular Edema
Diabetic Retinopathy(DR)
Retinal Vein Occlusion
Wet Age-Related Macular Degeneration (wAMD)
Dry Age-Related Macular Degeneration (dAMD)
Other
Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Application
Hospital
Clinic
Other
Players, stakeholders, and other participants in the global Macular Degeneration (AMD) and Other Retinal Diseases market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Macular Degeneration (AMD) and Other Retinal Diseases market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Macular Degeneration (AMD) and Other Retinal Diseases market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Macular Degeneration (AMD) and Other Retinal Diseases market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Macular Degeneration (AMD) and Other Retinal Diseases market.
The following players are covered in this report:
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
Merck
Allergan
Santen Pharmaceutical
GlaxoSmithKline Pharmaceuticals
Pfizer
Acucela
Valent Pharmaceuticals
IVERIC
Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Type
Macular Degeneration
Diabetic Macular Edema
Diabetic Retinopathy(DR)
Retinal Vein Occlusion
Wet Age-Related Macular Degeneration (wAMD)
Dry Age-Related Macular Degeneration (dAMD)
Other
Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Application
Hospital
Clinic
Other
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Macular Degeneration (AMD) and Other Retinal Diseases Revenue
1.4 Market Analysis by Type
1.4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Macular Degeneration
1.4.3 Diabetic Macular Edema
1.4.4 Diabetic Retinopathy(DR)
1.4.5 Retinal Vein Occlusion
1.4.6 Wet Age-Related Macular Degeneration (wAMD)
1.4.7 Dry Age-Related Macular Degeneration (dAMD)
1.4.8 Other
1.5 Market by Application
1.5.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Macular Degeneration (AMD) and Other Retinal Diseases Market Perspective (2015-2026)
2.2 Macular Degeneration (AMD) and Other Retinal Diseases Growth Trends by Regions
2.2.1 Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Share by Regions (2015-2020)
2.2.3 Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Macular Degeneration (AMD) and Other Retinal Diseases Market Growth Strategy
2.3.6 Primary Interviews with Key Macular Degeneration (AMD) and Other Retinal Diseases Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Market Size
3.1.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue (2015-2020)
3.1.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Players (2015-2020)
3.1.3 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio
3.2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Macular Degeneration (AMD) and Other Retinal Diseases Revenue in 2019
3.3 Macular Degeneration (AMD) and Other Retinal Diseases Key Players Head office and Area Served
3.4 Key Players Macular Degeneration (AMD) and Other Retinal Diseases Product Solution and Service
3.5 Date of Enter into Macular Degeneration (AMD) and Other Retinal Diseases Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Type (2015-2020)
4.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Type (2021-2026)
5 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Application (2015-2026)
5.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
5.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
6.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in North America (2019-2020)
6.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
6.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
7 Europe
7.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
7.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in Europe (2019-2020)
7.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
7.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
8 China
8.1 China Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
8.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in China (2019-2020)
8.3 China Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
8.4 China Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
9 Japan
9.1 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
9.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in Japan (2019-2020)
9.3 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
9.4 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
10.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
10.4 Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
11 India
11.1 India Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
11.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in India (2019-2020)
11.3 India Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
11.4 India Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
12.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in Central & South America (2019-2020)
12.3 Central & South America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
12.4 Central & South America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
13Key Players Profiles
13.1 Regeneron Pharmaceuticals
13.1.1 Regeneron Pharmaceuticals Company Details
13.1.2 Regeneron Pharmaceuticals Business Overview and Its Total Revenue
13.1.3 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.1.4 Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020))
13.1.5 Regeneron Pharmaceuticals Recent Development
13.2 Bayer HealthCare
13.2.1 Bayer HealthCare Company Details
13.2.2 Bayer HealthCare Business Overview and Its Total Revenue
13.2.3 Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.2.4 Bayer HealthCare Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.2.5 Bayer HealthCare Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview and Its Total Revenue
13.3.3 Novartis Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.3.4 Novartis Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 Roche
13.4.1 Roche Company Details
13.4.2 Roche Business Overview and Its Total Revenue
13.4.3 Roche Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.4.4 Roche Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.4.5 Roche Recent Development
13.5 Kanghong Pharma
13.5.1 Kanghong Pharma Company Details
13.5.2 Kanghong Pharma Business Overview and Its Total Revenue
13.5.3 Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.5.4 Kanghong Pharma Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.5.5 Kanghong Pharma Recent Development
13.6 Merck
13.6.1 Merck Company Details
13.6.2 Merck Business Overview and Its Total Revenue
13.6.3 Merck Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.6.4 Merck Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.6.5 Merck Recent Development
13.7 Allergan
13.7.1 Allergan Company Details
13.7.2 Allergan Business Overview and Its Total Revenue
13.7.3 Allergan Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.7.4 Allergan Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.7.5 Allergan Recent Development
13.8 Santen Pharmaceutical
13.8.1 Santen Pharmaceutical Company Details
13.8.2 Santen Pharmaceutical Business Overview and Its Total Revenue
13.8.3 Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.8.4 Santen Pharmaceutical Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.8.5 Santen Pharmaceutical Recent Development
13.9 GlaxoSmithKline Pharmaceuticals
13.9.1 GlaxoSmithKline Pharmaceuticals Company Details
13.9.2 GlaxoSmithKline Pharmaceuticals Business Overview and Its Total Revenue
13.9.3 GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.9.4 GlaxoSmithKline Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.9.5 GlaxoSmithKline Pharmaceuticals Recent Development
13.10 Pfizer
13.10.1 Pfizer Company Details
13.10.2 Pfizer Business Overview and Its Total Revenue
13.10.3 Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.10.4 Pfizer Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.10.5 Pfizer Recent Development
13.11 Acucela
10.11.1 Acucela Company Details
10.11.2 Acucela Business Overview and Its Total Revenue
10.11.3 Acucela Macular Degeneration (AMD) and Other Retinal Diseases Introduction
10.11.4 Acucela Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
10.11.5 Acucela Recent Development
13.12 Valent Pharmaceuticals
10.12.1 Valent Pharmaceuticals Company Details
10.12.2 Valent Pharmaceuticals Business Overview and Its Total Revenue
10.12.3 Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction
10.12.4 Valent Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
10.12.5 Valent Pharmaceuticals Recent Development
13.13 IVERIC
10.13.1 IVERIC Company Details
10.13.2 IVERIC Business Overview and Its Total Revenue
10.13.3 IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Introduction
10.13.4 IVERIC Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
10.13.5 IVERIC Recent Development
14Analyst's Viewpoints/Conclusions
15Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Macular Degeneration (AMD) and Other Retinal Diseases Revenue
1.4 Market Analysis by Type
1.4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Macular Degeneration
1.4.3 Diabetic Macular Edema
1.4.4 Diabetic Retinopathy(DR)
1.4.5 Retinal Vein Occlusion
1.4.6 Wet Age-Related Macular Degeneration (wAMD)
1.4.7 Dry Age-Related Macular Degeneration (dAMD)
1.4.8 Other
1.5 Market by Application
1.5.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Macular Degeneration (AMD) and Other Retinal Diseases Market Perspective (2015-2026)
2.2 Macular Degeneration (AMD) and Other Retinal Diseases Growth Trends by Regions
2.2.1 Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Share by Regions (2015-2020)
2.2.3 Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Macular Degeneration (AMD) and Other Retinal Diseases Market Growth Strategy
2.3.6 Primary Interviews with Key Macular Degeneration (AMD) and Other Retinal Diseases Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Market Size
3.1.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue (2015-2020)
3.1.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Players (2015-2020)
3.1.3 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio
3.2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Macular Degeneration (AMD) and Other Retinal Diseases Revenue in 2019
3.3 Macular Degeneration (AMD) and Other Retinal Diseases Key Players Head office and Area Served
3.4 Key Players Macular Degeneration (AMD) and Other Retinal Diseases Product Solution and Service
3.5 Date of Enter into Macular Degeneration (AMD) and Other Retinal Diseases Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Type (2015-2020)
4.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Type (2021-2026)
5 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Application (2015-2026)
5.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
5.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
6.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in North America (2019-2020)
6.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
6.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
7 Europe
7.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
7.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in Europe (2019-2020)
7.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
7.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
8 China
8.1 China Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
8.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in China (2019-2020)
8.3 China Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
8.4 China Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
9 Japan
9.1 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
9.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in Japan (2019-2020)
9.3 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
9.4 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
10.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
10.4 Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
11 India
11.1 India Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
11.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in India (2019-2020)
11.3 India Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
11.4 India Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2015-2020)
12.2 Macular Degeneration (AMD) and Other Retinal Diseases Key Players in Central & South America (2019-2020)
12.3 Central & South America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2015-2020)
12.4 Central & South America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2015-2020)
13Key Players Profiles
13.1 Regeneron Pharmaceuticals
13.1.1 Regeneron Pharmaceuticals Company Details
13.1.2 Regeneron Pharmaceuticals Business Overview and Its Total Revenue
13.1.3 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.1.4 Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020))
13.1.5 Regeneron Pharmaceuticals Recent Development
13.2 Bayer HealthCare
13.2.1 Bayer HealthCare Company Details
13.2.2 Bayer HealthCare Business Overview and Its Total Revenue
13.2.3 Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.2.4 Bayer HealthCare Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.2.5 Bayer HealthCare Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview and Its Total Revenue
13.3.3 Novartis Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.3.4 Novartis Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 Roche
13.4.1 Roche Company Details
13.4.2 Roche Business Overview and Its Total Revenue
13.4.3 Roche Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.4.4 Roche Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.4.5 Roche Recent Development
13.5 Kanghong Pharma
13.5.1 Kanghong Pharma Company Details
13.5.2 Kanghong Pharma Business Overview and Its Total Revenue
13.5.3 Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.5.4 Kanghong Pharma Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.5.5 Kanghong Pharma Recent Development
13.6 Merck
13.6.1 Merck Company Details
13.6.2 Merck Business Overview and Its Total Revenue
13.6.3 Merck Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.6.4 Merck Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.6.5 Merck Recent Development
13.7 Allergan
13.7.1 Allergan Company Details
13.7.2 Allergan Business Overview and Its Total Revenue
13.7.3 Allergan Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.7.4 Allergan Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.7.5 Allergan Recent Development
13.8 Santen Pharmaceutical
13.8.1 Santen Pharmaceutical Company Details
13.8.2 Santen Pharmaceutical Business Overview and Its Total Revenue
13.8.3 Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.8.4 Santen Pharmaceutical Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.8.5 Santen Pharmaceutical Recent Development
13.9 GlaxoSmithKline Pharmaceuticals
13.9.1 GlaxoSmithKline Pharmaceuticals Company Details
13.9.2 GlaxoSmithKline Pharmaceuticals Business Overview and Its Total Revenue
13.9.3 GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.9.4 GlaxoSmithKline Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.9.5 GlaxoSmithKline Pharmaceuticals Recent Development
13.10 Pfizer
13.10.1 Pfizer Company Details
13.10.2 Pfizer Business Overview and Its Total Revenue
13.10.3 Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Introduction
13.10.4 Pfizer Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
13.10.5 Pfizer Recent Development
13.11 Acucela
10.11.1 Acucela Company Details
10.11.2 Acucela Business Overview and Its Total Revenue
10.11.3 Acucela Macular Degeneration (AMD) and Other Retinal Diseases Introduction
10.11.4 Acucela Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
10.11.5 Acucela Recent Development
13.12 Valent Pharmaceuticals
10.12.1 Valent Pharmaceuticals Company Details
10.12.2 Valent Pharmaceuticals Business Overview and Its Total Revenue
10.12.3 Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction
10.12.4 Valent Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
10.12.5 Valent Pharmaceuticals Recent Development
13.13 IVERIC
10.13.1 IVERIC Company Details
10.13.2 IVERIC Business Overview and Its Total Revenue
10.13.3 IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Introduction
10.13.4 IVERIC Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2015-2020)
10.13.5 IVERIC Recent Development
14Analyst's Viewpoints/Conclusions
15Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
